Acelyrin

ACELYRIN announced positive Phase 1/2 trial results for lonigutamab, a subcutaneous anti-IGF-1R treatment for Thyroid Eye Disease (TED), showing rapid improvements in proptosis and clinical activity score within 3 weeks. The treatment, well-tolerated with no serious adverse events, demonstrated potential for longer-term dosing to enhance clinical response depth and durability. A Phase 2b/3 trial is planned for 2024.

Acelyrin Inc. announced its Phase 2b/3 trial of Izokibep for psoriatic arthritis met the primary ACR50 endpoint at week 16 with high statistical significance. The trial showed improved responses in 160 mg weekly and bi-weekly doses, with a low discontinuation rate of less than 3%, and meaningful enthesitis resolution.

Phase 2b trial of izokibep for hidradenitis suppurativa showed significant clinical improvements, with a third of patients achieving HiSCR100 by week 16. Patients switching from placebo to izokibep at week 16 matched the response speed and magnitude of those starting treatment earlier. Izokibep demonstrated a favorable safety profile and potential for differentiation with higher clinical responses. Long-term data indicated no increased safety risks and further clinical improvements over time.

ACELYRIN's Phase 2b/3 trial of izokibep for psoriatic arthritis met the primary ACR50 endpoint at 16 weeks with high statistical significance, showing robust clinical responses and a favorable safety profile. Izokibep demonstrated potential for differentiation in enthesitis resolution and achieved meaningful benefits in severe cases.

Kessler Topaz Meltzer & Check, LLP announces a securities class action lawsuit against Acelyrin, Inc. for alleged federal securities law violations, including misleading statements and omissions. Acelyrin's stock plummeted after disappointing trial results and a disclosed testing protocol error. Investors have until January 16, 2024, to file as lead plaintiff.

A class action lawsuit alleges Acelyrin, Inc. and its officers violated federal securities laws by making false statements about izokibep's effectiveness and the company's prospects, leading to a significant stock price drop. Investors affected between May 4, 2023, and September 11, 2023, can join the lawsuit by January 16, 2024.

Acelyrin's stock dropped after disappointing Phase 2b trial results for izokibep in treating Hidradenitis Suppurativa. Despite not meeting the primary endpoint, early HiSCR100 responses and dose-effect data support further evaluation. Analysts maintain a Strong Buy rating for SLRN.

Acelyrin's IL-17A inhibitor, izokibep, did not meet the primary endpoint in a phase 2b/3 trial for hidradenitis suppurativa treatment, with 39% of patients on once-weekly 160 mg achieving HiSCR75 at 16 weeks vs. 29% on placebo. Despite high discontinuation rates and unexpected placebo response, izokibep showed potential in HiSCR100 and has an ongoing phase 3 trial.

ACELYRIN reported Phase 2b/3 trial data for izokibep showing early improvements in Hidradenitis Suppurativa patients, with Part B results expected Q3 2023. Psoriatic Arthritis trial enrollment completed, top-line data accelerated to Q1 2024. Strong cash position of $823M supports clinical programs. Leadership updates include Ken Lock as Chief Commercial Officer.